Research Publications

  1. ​McGahan, L. Pembrolizumab (Keytruda®) as first-line therapy for PD-L1- expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC). Horizon Scanning in Oncology No. 91. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; October 2019.
  2. McGahan, L. Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs). Horizon Scanning in Oncology No. 89. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; July 2019.
  3. ​McGahan, L. Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triplenegative breast cancer (aTNBC). Horizon Scanning in Oncology No. 87. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; March 2019.
  4. McGahan, L. Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenstrom’s macroglobulinemia. Horizon Scanning in Oncology No. 85. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; December 2018.
  5. ​McGahan, L. Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC). Horizon Scanning in Oncology No 83. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; September 2018.
  6. McGahan, L. Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). Horizon Scanning in Oncology No 80 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; June 2018. 
  7. McGahan, L. Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC). Horizon Scanning in Oncology No 78 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; February 2018.
  8. McGahan, L. Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small cell lung cancer after prior chemoradiotherapy. Horizon Scanning in Oncology No 76 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; December 2017. 
  9. McGahan, L. Olaparib (Lynparza®️) in patients with BRCA-mutated metastatic breast cancer. Horizon Scanning in Oncology No 71 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; September 2017.
  10. McGahan, L. Ceritinib (Zykadia™) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer. Horizon Scanning in Oncology No 69 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; June 2017.
  11. McGahan, L. Atezolizumab (Tecentriq®️) in previously treated non-small cell lung cancer (NSCLC). Horizon Scanning in Oncology No 68 ISSN-online 2076-5940. Vienna: Ludwig Boltzman Institute for Health Technology Assessment; April 2017.
  12. McGahan, L. Palbociclib (Ibrance™) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. Horizon Scanning in Oncology No 64 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; January 2017.
  13. McGahan, L. Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma. Horizon Scanning in Oncology No 61 ISSN online 2076-5940. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment; October 2016.
  14. Lambert, R, Vreugdenburg, TD, Marlow, N, Scott, NA, McGahan, L, Tivey, D. Practical applications of rapid review methods in the development of Australian health policy. Australian Health Review; accepted for publication 5 June 2016, published online 29 July 2016.
  15. Best practices for increasing attendance at outpatient addictions clinics. Rapid Review August 2015. Canadian Centre for Substance Abuse, freely accessible with login through the Treatment Space at http://www.eenetconnect.ca/g/treatment 
  16. McGahan, L, Scott, A. Hysteroscopy for abnormal uterine bleeding: review of clinical evidence and guidelines. Rapid Review March 2015. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
  17. McGahan, L, Scott, A. Tonsillectomy, adenoidectomy and adenotonsillectomy for obstructive sleep apnoea: review of clinical evidence and guidelines. Rapid Review February 2015. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
  18. Lopez-Olivo, MA, Amezaga Urruela, M, McGahan, L, Pollono, E.N., Suarez-Almazor, M.E. Rituxumab for rheumatoid arthritis (Review). Cochrane Database of Systematic Reviews 2015, Issue 1. Art.No.: CD007356. DOI: 10.1002/14651858.CD007356.pub2.
  19. McGahan, L, Scott, A. Arthroscopy for knee osteoarthritis: review of clinical evidence and guidelines. Rapid Review August 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
  20. McGahan, L, Scott, A. Herniorrhaphy for inguinal and femoral hernia: review of clinical evidence and guidelines.Rapid Review December 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
  21. Poulin, P., Chapman, K., McGahan, L., Austen, L., Schuler, T. Pre-operative skin antiseptics for preventing surgical site infections: what to do? Operating Room Nurses Association of Canada Journal; 32:3 (2014), 14-29.
  22. McGahan, L, Scott, A. Spinal surgery for chronic low back pain: review of clinical evidence and guidelines. Rapid Review June 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
  23. McGahan, L, Scott, A. Centralisation of bariatric surgery: policy implications. Rapid Review March 2014. Australian Safety and Efficacy Register of New Interventional Procedures—Surgical (ASERNIP-S), The Royal Australasian College of Surgeons.
  24. McGahan, L. Point-of-care phenotypic and genetic testing for patients with acute coronary syndrome. Issues in Emerging Health Technologies issue 123. Ottawa: Canadian Agency for Drugs and Technologies in Health; March 2013. 
  25. McGahan, L. Afrezza inhaled insulin for diabetes mellitus. Issues in Emerging Health Technologies issue 120. Ottawa: Canadian Agency for Drugs and Technologies in Health; January 2013. 
  26. McGahan, L. Hearing screening in pre-school aged children: a review of the clinical effectiveness and guidelines. Health Technology Inquiry Service Level 2. Ottawa: Canadian Agency for Drugs and Technologies in Health; November 2012. 
  27. McGahan, L. Metal-on-metal total hip replacements or hip resurfacing for adults: a review of clinical effectiveness and cost-effectiveness. Health Technology Inquiry Service Level 2. Ottawa: Canadian Agency for Drugs and Technologies in Health; November 2012.
  28. McGahan, L. Sterile pre-filled saline syringes for acute care patients: a review of clinical evidence, cost-effectiveness, evidence-based guidelines and safety. Health Technology Inquiry Service Level 2. Ottawa: Canadian Agency for Drugs and Technologies in Health; July 2012. 
  29. McGahan, L. Hydroxocobalamin for cyanide poisoning in the pre-hospital setting: a review of the comparative clinical effectiveness [CADTH HTIS-level 2 review June 2012] 
  30. McGahan, L. Buspirone for the treatment of anxiety: a review of clinical effectiveness, safety, and cost-effectiveness [CADTH HTIS-level 2 review May 2012] 
  31. McGahan, L. Opioid management practices for the prevention of drug diversion and misuse: a review of the clinical evidence and guidelines [CADTH HTIS-level 2 review April 2012] 
  32. McGahan, L. Triptans for migraine headaches: a review on safety [CADTH HTIS-level 2 review March 2012]
  33. Clinical and pharmacoeconomic review report [CADTH Common Drug Review March 2012] 
  34. McGahan, L. Lipid lowering agents for stroke prevention: a review of the clinical evidence, safety and guidelines. [CADTH HTIS-level 2 review, March 2012] 
  35. Clinical and pharmacoeconomic review report [CADTH Common Drug Review Feb 2012] 
  36. McGahan, L. Topical oxygen treatment for wound healing: a review of clinical and cost-effectiveness. [CADTH HTIS-level 2 review Jan 2012] 
  37. McGahan, L. Populations requiring foldable lenses for cataract surgery: a review of clinical evidence and guidelines. [CADTH HTIS-level 2 review, Oct 2011] 
  38. McGahan, L. The use of oxyNEO® and oxyContin® in adults: a review of the evidence on safety. [CADTH HTIS-level 2 review Sept 2011] 
  39. Clinical and pharmacoeconomic review report [CADTH Common Drug Review- Sept 2011]
  40. McGahan, L. Acetylsalicylic acid for venous thromboembolism prophylaxis: a review of clinical evidence, benefits, and harms.[CADTH HTIS –level 2 review Aug 2011] 
  41. McGahan, L., Antiplatelet agents for acute coronary syndrome: a review of the guidelines and recommendations. [CADTH HTIS –level 2 review, Aug 2011] 
  42. Kamel, C., McGahan, L., Polisena, J., Mierzwinski-Urban, M., Embil, J. Preoperative skin antiseptic preparations for preventing surgical site infections: a systematic review. Infection Control and Hospital Epidemiology; 33:6 (2012), 608-617.
  43. McGahan, L., Kamel, C., Mierzwinski-Urban, M. Preoperative skin antiseptic preparations and application techniques for preventing surgical site infections: a systematic review of the clinical evidence and guidelines. [CADTH HTIS –level 3 review, June 2011]
  44. McGahan, L., Calibration of blood glucose monitors for diabetes: a review of the clinical evidence and guidelines. [CADTH HTIS-level 2 review, June 2011] 
  45. Clinical and pharmacoeconomic review report [CADTH Common Drug Review- Jan 2011]
  46. Clinical and pharmacoeconomic review report [CADTH Common Drug Review- Nov 2010/Jan 2011/Oct 2011]
  47. McGahan, L. Methods to screen for hemoglobin S in blood donors selected for exchange transfusions: a review of the clinical effectiveness and guidelines. [CADTH HTIS –level 2 review, July 2010]
  48. Hodge, W., Brown, A., Kymes, S., Cruess, A., Blackhouse, G., Hopkins, R., McGahan, L., Sharma, S., Pan, I., Blair, J., Vollman, D. Pharmacological management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation. Can J Ophthalmol 2010;45:223-30. 
  49. Banerjee, S., Brown, A., McGahan, L., Asakawa, K., Hutton, B., Clark, M., Severn, M., Sharma, M., Cox, J.L. Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses. [Technology report number 133]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010. 
  50. Chen, S.Y., Russell, E., Banerjee, S., Hutton, B, Brown, A., Asakawa, K., McGahan, L., Clark, M., Severn, M., Cox, J., Sharma, M.  Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses. [Technology report number 131].  Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010. 
  51. Banerjee, S., Brown, A., Hutton, B., McGahan, L., Asakawa, K., Clark, M., Cox, JL., Sharma, M.  Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost-effectiveness analyses. [Technology report number 123].  Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009. 
  52. McGahan, L. Mechanical cardiopulmonary resuscitation versus manual cardiopulmonary resuscitation for cardiac arrest in pre-hospital and hospital settings.  [CADTH HTIS –level 2 review dated 30 May 2008] 
  53. McGahan, L. Diagnosis and treatment of autism: guidelines and clinical effectiveness.  [CADTH HTIS –level 2 review dated 30 April 2008] 
  54. McGahan, L.  Administration of intravenous medications to pediatric patients: guidelines and safety of intravenous push.[CADTH HTIS –level 2 review dated 4 April 2008]. 
  55. Brown, A., Hodge, W., Kymes, S., Cruess, A., Blackhouse, G., Hopkins, R., McGahan, L., Sharma, S., Pan, I., Blair, J., Vollman, D., Morrison, A.  Management of neovascular age-related macular degeneration: systematic drug class review and economic evaluation. [Technology report number 110]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. 
  56. McGahan, L.  Continuous erythropoietin receptor activator (Mircera) for renal anemia.  Issues in Emerging Health Technologies issue 113.  Ottawa: Canadian Agency for Drugs and technologies in Health; 2008. 
  57. Wells, P., Brown, A., Jaffey, J. McGahan, L., Poon, M, Cimon, K.  2007 Oct 116.  Safety and effectiveness of point-of-care monitoring devices in patients on oral anticoagulant therapy: a meta-analysis.  Open Medicine [Online] 1:3.  Available: 
  58. McGahan, L.  Cholesterol testing devices: clinical and cost-effectiveness. [CADTH HTIS –level 2 review dated 19 February 2008]. 
  59. McGahan, L.  Outpatient pulmonary vein ablation for atrial fibrillation: clinical and cost-effectiveness review. [CADTH HTIS –level 2 review dated 3 December 2007]. 
  60. McGahan, L. and M. Severn.  Comparative clinical effectiveness and safety of long-term subcutaneous insulin injections by site. [CADTH HTIS –level 1 review dated 30 August 2007]. 
  61. Membe, S., McGahan, L., Cimon, K., Gawal, M., Giammarco, R., Mierzwinski-Urban, M.  Triptans for acute migraine: comparative clinical effectiveness and cost-effectiveness [Technology report no 76].  Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007. 
  62. Brown, A., Wells, P., Jaffey, J., McGahan, L., Poon, M-C., Cimon, K., Campbell, K.  Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost-effectiveness [Technology report no 72.].  Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007. 
  63. McGahan, L., and R. Banks.  Aspheric and blue light-filtering intraocular lenses in patients with presbyopia and cataracts.  [CADTH HTIS –level 1 review dated 7 December 2006].
  64. Palylyk-Colwell, E. and L. McGahan.  Rituximab for rheumatoid arthritis. Issues in Emerging Health Technologies issue 89.  Ottawa: Canadian Agency for Drugs and Technologies in Health; September 2006. 
  65. McGahan, L. and T. Keating.  Hospital policy and formulary restrictions to reduce Clostridium difficile-associated diarrhea (CDAD).  [CADTH HTIS –level 2 review dated 12 May 2006] 
  66. Guidelines for economic evaluation of health technologies: Canada [3rd Edition].  Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006. L. McGahan drafted information regarding the evaluation of non-drug technologies. 
  67. McGahan, L., Mierzwinski-Urban, M., Keating, T.  Rituximab selective CD+ B-cell depletion therapy for rheumatoid arthritis: a systematic review of clinical trials. [CCOHTA HTIS –level 3 review dated 31 March 2006.] 
  68. McGahan, L., Kakuma R., Ho, C., Bassett, K., Noorani, H.Z., Joyce, J., Allanson, J., Taylor, S.  BRCA1 and BRCA2 predictive genetic testing for breast and ovarian cancers: a systematic review of clinical evidence [Technology report no. 66].  Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2006. 
  69. Hailey, D., Tran, K., Dales, R., Mensinkai, S. McGahan, L.  Recommendations and supporting evidence in guidelines for referral of patients to sleep laboratories.  Sleep Medicine Reviews 2006; 10: 287-299. 
  70. Hailey, D., Tran, K., Dales, R., Mensinkai, S., McGahan, L.  A review of guidelines for referral of patients to sleep laboratories [Technology report no. 55].  Ottawa:  Canadian Coordinating Office for Health Technology Assessment; 2005. 
  71. Garces, K., McCormick, A., McGahan, L., Skidmore, B.  Botulinum toxin A for upper and lower limb spasticity: a systematic review.  Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2004.  Technology report no. 51. 
  72. Brady, B., McGahan, L., Skidmore, B.  A systematic review of economic evidence on stroke rehabilitation services. International Journal of Technology Assessment in Health Care; 21:1 (2005), 15-21.   
  73. Noorani, H.Z., Brady, B., McGahan, L., Teasell, R., Skidmore, B., Doherty, T.J.  Stroke rehabilitation services: systematic reviews of the clinical and economic evidence.  Ottawa:  Canadian Coordinating Office for Health Technology Assessment; 2003.  Technology report no 35. 
  74. Grunfeld, E., Noorani, H.Z., McGahan, L., Paszat, L., Coyle, D., van Walraven, C., Joyce, J., Sawka, C.  Surveillance mammography after treatment of primary breast cancer: a systematic review.  The Breast 2002; 11(3):228-35. 
  75. L. McGahan.  Continuous glucose monitoring in the management of diabetes mellitus.  Issues in Emerging Health Technologies. 2002; May; (32)1-4.
  76. L. McGahan.  Behavioural interventions for preschool children with autism.  Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2001.  Technology Report no 18. 
  77. Paszat, L., Grunfeld, E., van Walraven, C., Coyle, D., Sawka, C., Yun, J., McGahan, L., Noorani, HZ.  A population-based cohort study of surveillance mammography after treatment of primary breast cancer.  Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2001.  Technology Report no 15. 
  78. L. McGahan.  Tenecteplase: single-bolus thrombolytic therapy for acute myocardial infarction.  Issues in Emerging Health Technologies. 2001; Jan; (13)1-4. 
  79. L. McGahan.  Lotronex: therapy for diarrhea predominant irritable bowel syndrome.  Issues in Emerging Health Technologies. 2000; Oct; (11)1-4.  
  80. McGahan, L. and H.Z. Noorani.  Surveillance mammography after treatment for primary breast cancer.  Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2000. 
  81. L. McGahan.  Etanercept: anti-tumour necrosis factor therapy for rheumatoid arthritis.   Issues in Emerging Health Technologies. 1999; Oct; (8)1-4. 
  82. Noorani, H.Z. and L. McGahan.  Criteria for selection of adult recipients for heart, cadaveric kidney, and liver transplantation.   Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1999. 
  83. Noorani, H.Z. and L. McGahan.  Predictive genetic testing for breast and prostate cancer.  Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1999. 
  84. L. McGahan.  The Heart Laser: transmyocardial revascularization treatment of angina pectoris.   Issues in Emerging Health Technologies. 1998; (5)1-4. 
  85. L. McGahan.  Herceptin: monoclonal antibody therapy for metastatic breast cancer.  Issues in Emerging Health Technologies.1998; (4)1-4. 
  86. Noorani, H.Z. and L. McGahan.  Ethical, psycho-social and policy implications arising from predictive genetic testing for breast and prostate cancer.  Health Law Review. 98/99; 7(3):14-15. 


 L. McGahan Consulting  /  Ottawa, ON, Canada  /  T: 613 867 5497  /  E: info@evidencebasedhealthcare.co
Content Copyright 2013 L. McGahan Consulting. All rights reserved.